In This Section
Ira Pastan, MD

Ira Pastan, MD

National Cancer Institute
Bethesda, Maryland

Class of 2025

For visionary contributions to cancer therapy through the development of recombinant immunotoxins, a groundbreaking class of targeted drugs that selectively kill cancer cells, in turn revolutionizing treatments for solid tumors, leukemia, and mesothelioma; and for advancing the field of receptor biology, which has ultimately contributed to the establishment of targeted antibodies as a cancer therapy.

*Full-length biography in in development

[Institutional affiliations listed for Fellows reflect those held at the time of their induction into the AACR Academy.]